Home › Overweight › NCT07589608

A Study to Investigate Weight Management With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or Overweight

A Phase 2b, Parallel-Group, Double-Blind, Placebo-Controlled Study to Investigate Weight Management With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or Overweight and Without Type 2 Diabetes

Who can join

Ages 18 to 75 · All sexes

Inclusion Criteria:

* See Master Protocol CWMM (NCT06143956) for inclusion criteria

Exclusion Criteria:

In addition to exclusion criteria in Master Protocol CWMM (NCT06143956):

* Have type 1 diabetes or type 2 diabetes
* Have an ongoing history of bradyarrhythmia and/or sinus bradycardia
* Have an elevated resting pulse rate (greater than 100 bpm) or reduced resting pulse rate (less than 60 bpm)
* Have a history of acute or chronic pancreatitis
* All concomitant medications should be at a stable dose for at least 3 months prior to screening

About the study

The main purpose of this study, performed under the master protocol W8M-MC-CWMM (NCT06143956), is to examine the body weight-lowering efficacy and safety of macupatide plus eloralintide compared with placebo in participants with obesity or overweight and without type 2 diabetes. Participation will last about 64 weeks.

What is being tested

• Macupatide (drug)
• Eloralintide (drug)
• Placebo (drug)

Sponsor: Eli Lilly and Company · Participants: 400 · Started: May 15, 2026

Contact the study team

• Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or · Phone: 317-615-4559

Official record on ClinicalTrials.gov — NCT07589608

Locations in the U.S.

Conditions

• Overweight
• Obesity

From ClinicalTrials.gov, data retrieved Sep 29, 2026. Each study sets its own eligibility; the study team decides who can join.